Strategic Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.86M | Buy |
2,018
+25
| +1% | +$25.3K | 0.31% | 76 |
|
|
2025
Q4 | $2.14M | Buy |
1,993
+77
| +4% | +$73.6K | 0.34% | 72 |
|
|
2025
Q3 | $1.46M | Sell |
1,916
-38
| -2% | -$28.3K | 0.23% | 82 |
|
|
2025
Q2 | $1.52M | Buy |
1,954
+250
| +15% | +$194K | 0.3% | 69 |
|
|
2025
Q1 | $1.41M | Sell |
1,704
-75
| -4% | -$62.4K | 0.27% | 79 |
|
|
2024
Q4 | $1.37M | Buy |
1,779
+146
| +9% | +$121K | 0.25% | 81 |
|
|
2024
Q3 | $1.45M | Buy |
1,633
+28
| +2% | +$25.2K | 0.27% | 79 |
|
|
2024
Q2 | $1.45M | Buy |
1,605
+44
| +3% | +$35.2K | 0.28% | 75 |
|
|
2024
Q1 | $1.21M | Buy |
1,561
+333
| +27% | +$237K | 0.24% | 87 |
|
|
2023
Q4 | $716K | Buy |
1,228
+84
| +7% | +$49K | 0.14% | 125 |
|
|
2023
Q3 | $615K | Buy |
1,144
+55
| +5% | +$28.3K | 0.12% | 127 |
|
|
2023
Q2 | $511K | Buy |
1,089
+73
| +7% | +$30.6K | 0.1% | 136 |
|
|
2023
Q1 | $349K | Buy |
1,016
+129
| +15% | +$43.5K | 0.07% | 153 |
|
|
2022
Q4 | $324K | Buy |
887
+53
| +6% | +$18.8K | 0.07% | 150 |
|
|
2022
Q3 | $269K | Buy |
834
+185
| +29% | +$58.6K | 0.06% | 157 |
|
|
2022
Q2 | $210K | Buy |
+649
| New | +$195K | 0.04% | 176 |
|
|
2017
Q4 | – | Sell |
-5,023
| Closed | -$430K | – | 141 |
|
|
2017
Q3 | $430K | Buy |
5,023
+258
| +5% | +$21.2K | 0.19% | 109 |
|
|
2017
Q2 | $392K | Buy |
4,765
+58
| +1% | +$4.73K | 0.18% | 110 |
|
|
2017
Q1 | $396K | Buy |
+4,707
| New | +$377K | 0.19% | 103 |
|
|
2016
Q4 | – | Sell |
-20,189
| Closed | -$1.62M | – | 128 |
|
|
2016
Q3 | $1.62M | Sell |
20,189
-489
| -2% | -$39.1K | 0.91% | 38 |
|
|
2016
Q2 | $1.63M | Buy |
20,678
+6,422
| +45% | +$483K | 0.94% | 38 |
|
|
2016
Q1 | $1.03M | Sell |
14,256
-689
| -5% | -$52.1K | 0.58% | 56 |
|
|
2015
Q4 | $1.26M | Buy |
14,945
+315
| +2% | +$26.1K | 0.82% | 45 |
|
|
2015
Q3 | $1.22M | Sell |
14,630
-1,000
| -6% | -$84.4K | 0.85% | 41 |
|
|
2015
Q2 | $1.3M | Hold |
15,630
| – | – | 0.83% | 38 |
|
|
2015
Q1 | $972K | Buy |
15,630
+1,000
| +7% | +$71.2K | 0.62% | 54 |
|
|
2014
Q4 | $1.01M | Hold |
14,630
| – | – | 0.66% | 52 |
|
|
2014
Q3 | $949K | Sell |
14,630
-1,000
| -6% | -$63.3K | 0.62% | 57 |
|
|
2014
Q2 | $972K | Sell |
15,630
-65
| -0.4% | -$3.88K | 0.62% | 54 |
|
|
2014
Q1 | $924K | Hold |
15,695
| – | – | 0.62% | 54 |
|
|
2013
Q4 | $800K | Buy |
15,695
+1,500
| +11% | +$75.1K | 0.54% | 63 |
|
|
2013
Q3 | $714K | Buy |
+14,195
| New | +$743K | 0.59% | 58 |
|
Other funds holding LLY
VCM
VPM
Strategic Advisors's LLY Position: Q1 2026 in Review
Strategic Advisors increased its Eli Lilly (LLY) stake by 1.3% in Q1 2026, buying an estimated $25.3K and bringing the position to 2,018 shares worth $1.86M. The position accounts for 0.31% of the portfolio, ranked #76.
Strategic Advisors first reported a position in LLY in Q3 2013 and has held it in 32 quarters since. The position peaked at $2.14M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Strategic Advisors held 2,018 shares of Eli Lilly worth $1.86M as of Q1 2026.
- Strategic Advisors bought 25 Eli Lilly shares in Q1 2026, an estimated $25.3K.
- Eli Lilly made up 0.31% of Strategic Advisors's portfolio in Q1 2026, its #76 holding.
- Strategic Advisors first reported a position in Eli Lilly in Q3 2013 and has held it in 32 quarters since.
- Strategic Advisors's Eli Lilly position peaked at $2.14M in Q4 2025.
- 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Strategic Advisors's 13F filing for Q1 2026, filed 14 May 2026.